Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Nexavar (Sorafenib) – India: A small step for Natco, a giant leap for generic drugs: India’s first compulsory licensing application filed (Spicy IP) (Patent Circle)

Glivec (Imatinib) – India: Final hearing in Novartis’ Glivec case begins in Supreme Court (GenericsWeb) (Spicy IP) (SiNApSE)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Medicines Patent Pool faces licensing issues (Spicy IP)

Australia: Pharmaceuticals – copyright in PIs and indirect patent infringement: Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3) (Mallesons)

China: One out of three seeds in China infringes patents (IP Dragon)

EU: More comments to the AG opinion in Medeva (The SPC Blog)

EU: Patent term extensions – uncertainty and disharmony: an overview (The SPC Blog)

India: NGO alleges ‘bio-piracy’ by Monsanto’s Indian subsidiary & its collaborators: True or false? (Spicy IP)

Netherlands: Danisco v. Novozymes – DC The Hague v. Opposition Division (Kluwer Patent Blog)

US: House legislators lobby to exclude 12-year data exclusivity period from free trade agreement (Patent Docs)

US: Legislators urge President to include 12-year data exclusivity period in free trade agreement (Patent Docs)

US: AMP v. PTO does not appear to invalidate very many gene patent method claims (Holman’s Biotech IP Blog)

US: Machine-or-transformation test after Myriad: Implications to the prosecution of process claims (Patent Law Practice Center)

US: Unsuccessful Qui Tam plaintiff asserting false marking claim not immune from costs award: Promote Innovation v Roche Diagnostics (Docket Report)

US: FDA releases two medical device draft guidances (FDA Law Blog)

US: BIO: Unleashing the promise of biotechnology (pt.4) (Patent Baristas)

 

Products

Angiomax (Bivalirudin) – US: Angiomax – the other patent battle: The Medicines Company v Teva (FDA Law Blog)

Dilaudid (Hydromorphone) – US: Purdue Pharmaceutical Products files patent infringement suit against Hikma and West-Ward Pharmaceuticals in response to Para IV certification filing (Patent Docs)

Epzicom (Abacavir, Lamivudine) – US: Viiv Healthcare file patent infringement complaint against Teva in response to Para IV certification (Patent Docs)

Gemzar (Gemcitabine) – US: ITC: Motion for presumption of infringement denied in Gemcitabine investigation (ITC 337 Update)

Glivec (Imatinib) – India: Final hearing in Novartis’ Glivec case begins in Supreme Court (GenericsWeb) (Spicy IP) (SiNApSE)

Lexapro (Escitalopram) – Germany: Escitalopram revisited – Federal Patent Court issues written grounds – SPC can only be revoked if Escitalopram claimed in SPC is not a product different from racemic Citalopram (Kluwer Patent Blog) (The SPC Blog)

Morphine Sulphate – US: FDA says Tenth Circuit should say adieu to grandfather drug case without much ado; not so fast, says Cody/Lannett (FDA Law Blog)

Nexavar (Sorafenib) – India: A small step for Natco, a giant leap for generic drugs: India’s first compulsory licensing application filed (Spicy IP) (Patent Circle)

Nuedexta (Dextromethorphan hydrobromide, Quinidine sulphate) – US: Avanir Pharmaceuticals files patent infringement complaints against Par Pharmaceutical and Actavis following Para IV certification (Patent Docs)

Strattera (Atomoxetine) – US: CAFC confirms Strattera patent valid: Eli Lilly & Co v Actavis Elizabeth LLC (Patent Docs)

Suprep (Sodium sulphate, Potassium sulphate, Magnesium sulphate) – US: Braintree files patent infringement suit against Paddock in response to Para IV challenge (Patent Docs)